Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce Distribution Agreement

TURKU, Finland and LIMERICK, Ireland, January 21, 2013 /PRNewswire/ –

BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an
emerging leader in indications involving the treatment of chronically infected bone, and
Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused
on minimally-invasive regenerative therapies in bone and soft tissues, today announced the
signing of a multi-year exclusive distribution agreement. Under the agreement, Olympus
Biotech International will have exclusive distribution rights for the BonAlive(R) granules
product line in Germany, France and the UK. The product line covers regenerative products
for orthopaedic and trauma surgeries.

(Logo:
http://photos.prnewswire.com/prnh/20130121/589026-a )

(Logo:
http://photos.prnewswire.com/prnh/20130121/589026-b )

The agreement is an important milestone in the commercialization strategy of the
BonAlive(R) granules product line in the pathway of further expanding the access to
hospitals in the large European markets.

“This newly established partnership enables us to work together with one of the most
prominent leaders in the field of regenerative medicine in providing a complete portfolio
of bone regeneration products to the community of orthopaedic and trauma surgeons” said
Dr. Fredrik Ollila, CEO of BonAlive Biomaterials Ltd. “The establishment of a complete
product offering will generate value and bring new opportunities in treatment of
chronically infected bone”.

“The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone
regeneration portfolio now also in the treatment of fractures and non-unions in patients
with chronic infections. During our thorough global assessment of different technologies
and options we were impressed by the clinical evidence and clinical data available for
BonAlive(R). We are very much convinced to have decided for a partnership with the company
having the right approach to improve patient outcome” said Florian Kemmerich, President of
Olympus Biotech International.

For more information about BonAlive Biomaterials Ltd, please visit

http://www.bonalive.com

For more information about Olympus Biotech, visit http://www.olympusbiotech.com

About BonAlive Biomaterials Ltd

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable medical
devices for bone regeneration. The focus is to provide world-leading biomaterial solutions
for the treatment of chronically infected bone. BonAlive(R) products are available in
Europe, Middle East, Asia-Pacific, Africa, Brazil and the USA through a professional
distributor network. The clinical use of BonAlive(R) is supported by a twenty year
research history including several randomized prospective trials in the field of spine,
benign bone tumor and trauma surgery. More than fifty peer reviewed articles have been
published about BonAlive(R).

About Olympus Biotech International Limited

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus
Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by
developing and distributing Regenerative Medicine that stimulates the intrinsic healing
capacity in the living body. Olympus Biotech provides minimally-invasive regenerative
therapies for bone and soft tissue including growth factors, scaffolds and cell harvesting
technologies as well as tools for access, placement and delivery.

For questions or additional information, please contact:

        Olympus Biotech International Limited
        Dirk Dembski
        Vice President Marketing and Business Development
        Olympus Biotech International
        Mobile +49-172-2492700
        dirk.dembski@olympusbiotech.com

        BonAlive Biomaterials Ltd:
        Fredrik Ollila, PhD
        Chief Executive Officer
        BonAlive Biomaterials Ltd
        Mobile +358(0)400-931-209
        Fax +358(0)421-917-744-00
        fredrik.ollila@bonalive.com

    Photo: 

http://photos.prnewswire.com/prnh/20130121/589026-a

http://photos.prnewswire.com/prnh/20130121/589026-b

SOURCE BonAlive Biomaterials Ltd